Amulticentre, Phase II, single-arm, interventional study of neoadjuvantdurvalumab and platinum-based chemotherapy (CT), followed by either surgery andadjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, inparticipants with resectable or borderline resectable stage IIB-IIIB Non-smallCell Lung Cancer (NSCLC)